Non-viral chimeric antigen receptor (CAR) T cells going viral

Area of Science:

• Immunotherapy
• Genetic Engineering
• Cell Therapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapy shows promise for B-cell malignancies but faces challenges in solid tumors.
• Current viral vector methods for CAR T-cell production are costly and face regulatory hurdles, limiting clinical translation.
• There is a need for more accessible and efficient methods for CAR T-cell development and delivery.

Purpose of the Study:

• To review recent advancements in non-viral approaches for CAR T-cell production.
• To discuss manufacturing requirements for clinical-grade non-viral CAR T-cells.
• To highlight necessary quality control adjustments for genomic characterization and genotoxicity assessment.

Main Methods:

• Exploration of non-viral gene delivery systems, including transposon/transposase and CRISPR/Cas systems.
• Analysis of strategies to overcome low knock-in efficiency and improve transgene expression.
• Review of manufacturing processes and quality control measures for clinical applications.

Main Results:

• Non-viral methods demonstrate potential for stable transgene insertion in CAR T-cells.
• Key challenges include low knock-in efficiency impacting transgene expression levels.
• Specific manufacturing and quality control adjustments are required for clinical translation.

Conclusions:

• Non-viral gene editing technologies offer a promising avenue for advancing CAR T-cell therapy, particularly for solid tumors.
• Addressing efficiency limitations and establishing robust manufacturing and quality control are critical for clinical success.
• Further research is needed to optimize these methods for widespread and cost-effective application.